XGEN:XETRA:XETRA-Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C USD Acc (EUR)

ETF | Others |

Last Closing

USD 28.33

Change

-0.02 (-0.07)%

Market Cap

N/A

Volume

117.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-29 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.48 (+0.95%)

USD 420.85B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.16 (+0.96%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.22 (+0.82%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.27 (+0.96%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.29 (+1.18%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

+0.35 (+0.78%)

USD 102.32B
8R80:XETRA Amundi Index Solutions - Amund..

+1.10 (+0.77%)

USD 102.11B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.53 (+1.07%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

+0.08 (+0.08%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+1.16 (+0.20%)

USD 80.38B

ETFs Containing XGEN:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.56% 36% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.56% 37% F 43% F
Trailing 12 Months  
Capital Gain 20.45% 52% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.45% 53% F 57% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -0.39% 24% F 26% F
Dividend Return -0.39% 23% F 25% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 5.00% 87% B+ 89% A-
Risk Adjusted Return -7.83% 23% F 24% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.